Everything below concerns LC-MS/MS. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-08-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
Analytical laboratories typically identify cardarine and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is a common matrix in anti-doping testing, while blood and tissue may be used in research settings. Detection windows depend on the assay, the sample matrix, and the compound's metabolism. Because cardarine is extensively metabolized, laboratories often target specific metabolites to improve sensitivity and confirmation. Reference standards are required for reliable quantification. Method validation includes checks for selectivity, linearity, and carryover.
A persistent misconception is that cardarine is a fat-burning drug or a safe alternative to anabolic steroids. No approved therapeutic product exists, and human safety data are limited. The tumor findings in rodents remain a central concern in scientific reviews. Products sold online may contain inaccurate labels, impurities, or different compounds entirely, which complicates any assessment of effects. Independent testing of such products has reported frequent mislabeling. For these reasons, discussions in the literature emphasize risks and unknowns rather than benefits.
Cardarine is not approved for human therapeutic use in any major jurisdiction. It appears on the World Anti-Doping Agency Prohibited List as a PPARδ agonist within the hormone and metabolic modulators category. Sports organizations test for it because it has been detected in athlete samples and seized products. Regulatory actions against marketed research chemical versions have occurred in several countries, though enforcement varies. Availability through unregulated channels complicates oversight.
In laboratory settings, cardarine is studied as a tool compound for probing PPARδ biology. Published experiments often use cell cultures, rodent models, or isolated tissues. Some investigations focus on metabolic effects, while others assess potential risks such as carcinogenicity observed in long-term animal studies. Because human trials are sparse, most knowledge comes from preclinical work and adverse event reports. Scientific literature frequently notes the gap between animal findings and human outcomes. The compound is not a dietary supplement and is not intended for human consumption.
Cardarine is a common name for GW501516, a synthetic compound developed in the 1990s through research collaborations involving GlaxoSmithKline. It belongs to a class of molecules known as peroxisome proliferator-activated receptor delta agonists. Early studies explored its effects on lipid metabolism and energy expenditure in animal models. The compound was never approved as a human medicine, and clinical development was discontinued. In the years since, it has appeared in fitness and bodybuilding communities as a performance-enhancing substance. Regulatory agencies classify it as an unapproved drug.
PPARδ is a nuclear receptor that regulates gene expression related to fatty acid oxidation, glucose homeostasis, and mitochondrial function. GW501516 binds to this receptor with high affinity and activates downstream signaling in skeletal muscle and other tissues. Animal studies reported increased endurance and altered fuel preference, but human data remain limited and inconsistent. The precise relationship between receptor activation and observed physiological changes is still an area of active investigation. Researchers have also examined whether the compound affects inflammation or cell proliferation. No approved therapeutic indication exists for cardarine.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved for human therapeutic use | No marketing authorization identified in major jurisdictions. |
| Anti-doping class | PPARδ agonist; hormone and metabolic modulators | Listed on the WADA Prohibited List. |
| Common test matrix | Urine | Also blood and tissue in research settings. |
| Typical analytical method | LC-MS/MS | Targets parent compound and metabolites. |
| Major safety signal | Tumor findings in rodents | Human relevance not established; limited human data. |
Literature on cardarine often separates receptor pharmacology from toxicology. Mechanistic papers describe PPARδ activation and gene expression changes, while safety assessments focus on carcinogenicity and species differences. Questions remain about whether rodent tumors arise through PPARδ-dependent or off-target mechanisms. Another open area is how human metabolism and exposure compare with those in animal studies. Analytical methods such as liquid chromatography–mass spectrometry are used to confirm identity in biological and product samples.
GW501516 acts as an agonist at the peroxisome proliferator-activated receptor delta, a nuclear receptor that regulates gene expression. Activation shifts transcription toward genes involved in fatty acid uptake, oxidation, and energy expenditure. The compound does not bind the androgen receptor and therefore differs from anabolic steroids and SARMs. In rodent models, this metabolic shift has been linked to increased running endurance and reduced fat accumulation. The exact downstream pathways in humans remain incompletely characterized.
Products sold as cardarine have been found to contain incorrect compounds, variable amounts, or no active ingredient at all. Independent testing is required to verify identity and purity. Common analytical approaches include high-performance liquid chromatography, mass spectrometry, and nuclear magnetic resonance for structural confirmation. These methods can distinguish GW501516 from related PPAR agonists and from unrelated steroids. For regulators and researchers, such verification is central to interpreting both biological results and adverse event reports.
Cardarine is prohibited in competitive sport under the World Anti-Doping Agency code, where it is classified as a metabolic modulator. It is not approved as a prescription medicine in the United States, European Union, or other major markets. Regulatory action has focused on its presence in sports and in products marketed as research chemicals. Because it has no accepted medical indication, supply is often unregulated. This status creates legal and safety uncertainties for anyone who encounters the substance.
Anti-doping laboratories detect GW501516 and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is the most common matrix, though blood and dried blood spots may also be used in some programs. Detection depends on factors such as dose, timing, metabolism, and the sensitivity of the assay. Published methods describe limits of detection in the low nanogram per milliliter range for related compounds. Exact detection windows are not fixed for all situations and remain an area of ongoing study.
Because cardarine is not an approved medicine, no pharmacopeial monograph defines its identity, purity, or storage requirements. Laboratories typically rely on in-house methods and reference standards when testing materials labeled as GW501516. Certificates of analysis may report purity and identity for a specific batch, but their scope varies and they do not guarantee safety or legal status. Independent verification can include high-performance liquid chromatography, mass spectrometry, nuclear magnetic resonance, and elemental analysis. The distinction between research chemical labeling and human use is significant because quality standards and oversight differ.
Cardarine can be detected in biological samples and product materials using liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS). The method separates compounds by chromatography and identifies them by mass-to-charge transitions, allowing low-level detection in urine or blood. Sample preparation often involves enzymatic hydrolysis, solid-phase extraction, or protein precipitation. Certified reference materials and isotope-labeled internal standards improve quantification. Detection windows depend on metabolism, matrix, and assay sensitivity, so no single universal window applies.
Regulatory treatment of cardarine differs by context and jurisdiction. In competitive sport, the World Anti-Doping Agency lists PPARδ agonists, including GW501516, as prohibited at all times. Outside sport, it lacks approval as a prescription medicine in major drug markets, and products sold for human consumption may be treated as unapproved drugs. Some countries also restrict importation or sale through general consumer protection and medicines laws. These classifications affect availability, testing, and legal risk without establishing therapeutic value.
=== Research === The company has more than 1,200 researchers working across its 12 Research & Development centers around the world. The company is focused on the development of potential new treatment options derived both from human plasma as well as a new class of recombinant antibody drugs. Grifols is researching a number of pathologies – from immunodeficiencies to respiratory disorders to age-related conditions – to create new therapeutics. It is also developing new diagnostics for blood screening.
In populations with a low risk for type 2 diabetes, in lean subjects and women with auto-antibodies, there is a higher rate of women developing type 1 diabetes (LADA). Children of women with GDM have an increased risk for childhood and adult obesity and an increased risk of glucose intolerance and type 2 diabetes later in life. This risk relates to increased maternal glucose values. It is currently unclear how much genetic susceptibility and environmental factors contribute to this risk, and whether treatment of GDM can influence this outcome. The relative benefits and harms of different oral anti-diabetic medications are not yet well understood as of 2017. There are scarce statistical data on the risk of other conditions in women with GDM; in the Jerusalem Perinatal study, 410 out of 37,962 women were reported to have GDM, and there was a tendency towards more breast and pancreatic cancer, but more research is needed to confirm this finding. Research is being conducted to develop a web-based clinical decision support system for GDM prediction using machine learning techniques. Results so far demonstrated great potential in clinical practicality for automatic GDM prognosis.
1985 Goldenes Ehrenzeichen, Republic of Austria 1994 Austrian Decoration for Science and Art, Republic of Austria 1997 Honorary Member, Slovak Chemical Society 2003 Cross of Merits, State of Tyrol 2004 Cross of Merits, Austria 2007 Cross of Honours in Science and Arts first class, Republic of Austria 2008 Jan-Weber-Medal of the Slovak Pharmaceutical Society 2010 Sitara-e-Qaid-i-Azam (Civil decoration of Pakistan) 2011 Knight Grand Cross (First Class of The Most Exalted Order of the White Elephant with Slash) According to the Theoretical Chemistry Genealogy Project, Bernd Michael Rode is the most successful doctoral thesis supervisor of German-speaking countries in the field of Theoretical Chemistry. Between 1976 and 2011 Prof. Rode has led not less than 70 students to their Ph.D. degree. Due to his close contacts to South-East-Asia many of them come from Asian countries.
The company's headquarters is the Starbucks Center in Seattle, Washington, United States, where 3,750 people worked as of 2023. The main building in the Starbucks complex in SODO, where the company leases 1.29 million square feet (120,000 m2) of space, was previously a Sears mail order distribution center until 1987. In 2026, Starbucks announced the long-term lease of 250,000 square feet (23,000 m2) for a regional office in Nashville, Tennessee.
=== Receptor Genetics === Four RXFPs in humans are located in different linkage groups. Additionally there are two RXFP pseudogenes ("RXFP3-3" and "RXFP2-like") which have functional counterparts in other species.
Sources: en.wikipedia.org
When the patent period of a drug ends, a generic version is usually made. With conventional small-molecule drugs, it is possible to create a generic that is exactly the same as the original because small-molecule drugs can be characterized down to a single atom. However, the structure of biologics is far more complex and can't be fully characterized with current analytical techniques. Also, the cell-based manufacturing process of biologics results in undefinable post-translational modifications. Thus, it is impossible to prove whether two biologics are exactly the same in every aspect. There are no generic versions of biologics. Instead there are biosimilars. Biosimilars are defined by the FDA as, "a biological product that is highly similar to and has no clinically meaningful differences from an existing FDA-approved reference product." Currently, the only two biologic treatments for IBD that have approved biosimilars are adalimumab and infliximab.
Collision-induced dissociation (CID), also known as collisionally activated dissociation (CAD), is a mass spectrometry technique to induce fragmentation of selected ions in the gas phase. The selected ions (typically molecular ions or protonated molecules) are usually accelerated by applying an electrical potential to increase the ion kinetic energy and then allowed to collide with neutral molecules (often helium, nitrogen, or argon). In the collision, some of the kinetic energy is converted into internal energy which results in bond breakage and the fragmentation of the molecular ion into smaller fragments. These fragment ions can then be analyzed by tandem mass spectrometry. CID and the fragment ions produced by CID are used for several purposes. Partial or complete structural determination can be achieved. In some cases, identity can be established based on previous knowledge without determining structure. Another use is in simply achieving more sensitive and specific detection. By detecting a unique fragment ion, the precursor ion can be detected in the presence of other ions of the same m/z value (mass-to-charge ratio), reducing the background and increasing the limit of detection.
models the transition rate from the compartment of susceptible individuals to the compartment of infectious individuals, so that it is called the force of infection. However, for large classes of communicable diseases it is more realistic to consider a force of infection that does not depend on the absolute number of infectious subjects, but on their fraction (with respect to the total constant population
Eosin is the name of several fluorescent acidic compounds which bind to and form salts with basic, or eosinophilic, compounds like proteins containing basic amino acid residues such as histidine, arginine and lysine, and stains them dark red or pink as a result of the actions of bromine on eosin. In addition to staining proteins in the cytoplasm, it can be used to stain collagen and muscle fibers for examination under the microscope. Structures that stain readily with eosin are termed eosinophilic. In the field of histology, Eosin Y is the form of eosin used most often as a histologic stain.
Berry filed a lawsuit against Gulf Coast Wings, the local franchisee, and later reached a settlement. In 2004, it was found that job applicants to a Hooters in West Covina, California, were secretly filmed while undressing, prompting a civil suit filed against the national restaurant chain in Los Angeles Superior Court. The company responded to the incident with additional employee training. In 2009, Nikolai Grushevski, a man from Corpus Christi, Texas, filed a lawsuit because Hooters would not hire him as a waiter. Grushevski and Hooters reached a confidential settlement on April 13. In September 2009, the US Equal Employment Opportunity Commission filed a lawsuit against a North Carolina charter airline (formerly Hooters Air, owned by Hooters of America) on behalf of Chau Nguyen, an Asian flight attendant fired three years prior after complaining only white workers were being promoted. In May 2010, a lawsuit was filed against Hooters in Michigan after an employee was given a job performance review and was told that her shirt and short size could use some improvement by two women who held positions at the headquarters in Atlanta. Michigan is the only state that includes height and weight as bounds for non-discrimination in hiring. The plaintiff alleges that she was made the offer of a free gym membership and told that if she did not improve in 30 days, her employment would be terminated. The company denied that they threatened to fire the plaintiffs, and the suit was settled out of court.
Sources: en.wikipedia.org
January 22 The United States leaves the World Health Organization. Trump's Executive Order 14253 is carried out, removing exhibits commemorating the history of slavery in the United States at the President's House. January 23 – The Office of Foreign Assets Control imposes sanctions on British-Palestinian activist Zaher Birawi, alleging that he has ties with Hamas. January 23–26 – A major winter storm and cold wave impact over 30 states and kill at least 85 people, with over 15 states of emergency being declared.
=== Bossa and Vertigo === By September 2017, Faliszek had joined London-based Bossa Studios, and led Bossa's new Seattle-based studio. He was working on an unannounced cooperative game that is "trying to do something new in the narrative space using [artificial intelligence]". In May 2018, Faliszek announced he had also joined the board of advisers for Vertigo Games, and will help support a virtual reality title they are currently developing. After about a year at Bossa, Faliszek and Bossa agreed that what Faliszek had planned was not working out, in part due to his envisioned game not being the type of product Bossa had worked on before, and Faliszek left the company early in 2019. By March 2019, he founded a new studio, Stray Bombay Company, along with Riot Games' Kimberly Voll, in essence to continue the development of the cooperative title. Faliszek had previously met Voll around 2012 while Valve was exploring the VR space, and had helped Voll get Radial Games Fantastic Contraption as a SteamVR launch title. Faliszek found Voll's focus on player interaction a key part of his idea for the cooperative game. Stray Bombay was backed financially by both Riot and Upfront Ventures. The company's first game is The Anacrusis, which was released via early access in January 2022, and fully launched December 5th, 2023. Starting around 2023, Faliszek began to post TikToks and YouTube videos about his time at Valve, experiences in the games industry, and his views on game design. He would make a video about Stop Killing Games, disagreeing with the movement.
GLP1 poly-agonist peptides are a class of drugs that activate multiple peptide hormone receptors including the glucagon-like peptide-1 (GLP-1) receptor. These drugs are developed for the same indications as GLP-1 receptor agonists—especially obesity, type 2 diabetes, and non-alcoholic fatty liver disease. Unlike GLP-1 mono-agonists, which target only the GLP-1 receptor, poly-agonists activate two or more incretin receptors, such as the gastric inhibitory polypeptide (GIP) receptor, which have distinct features but work together in metabolic regulation. GIP and GLP-1 are both naturally released from the gastrointestinal tract after eating, but act on different receptor distributions across tissues. GLP-1 receptors are concentrated in the pancreas, brain, and gastrointestinal tract, while GIP receptors are found primarily in the pancreas, brain, and adipose tissue. In healthy people, the combined incretin effect of GIP and GLP-1 accounts for around 50–70% of post-meal insulin secretion. This effect is substantially reduced in people with type 2 diabetes, providing evidence for therapies that activate both hormones. Poly-agonists are expected to provide superior efficacy with fewer adverse effects compared to GLP-1 mono-agonists, which are dose-limited by gastrointestinal disturbances. The effectiveness of multi-receptor agonists could possibly equal or exceed that of bariatric surgery. The first such drug to receive approval is tirzepatide, a dual agonist of GLP-1 and GIP receptors.
On 10 February 1999, the Forestry Corps HQ, Inner Mongolia Corps, Heilongjiang Corps, Jilin Corps and Yunnan Detachment (later upgraded to corps level) were founded, in 2002 the Sichuan Corps, Tibet Corps and Xinjiang Corps were founded, and in 2007 the Fujian Corps, the Gansu Corps and Mobile Detachment were founded. On 22 July 2009, the People's Armed Police Headquarters Helicopter Detachment was founded. It was stationed in Daqing and operated Z-8 Helicopters, which were used for search and rescue, personnel transport and firefighting. The Helicopter Detachment had the nickname "Heroic Firefighting Hawks". AC313s were also ordered. After the 2008 Sichuan Earthquake, the Forestry Corps deployed over 2000 personnel to assist with rescue efforts. In total, the forestry corps evacuated 14,000 people, rescued 8 survivors, recovered the bodies of 1,200 victim along with transporting 2,000 tonnes of aid, repairing 40 km of roads and rescuing 86 giant pandas. On 16 September 2015, the Forestry Corps Lijiang Detachment was deployed to Huaping county to conduct post-flood disaster relief efforts, rescuing 10 people and transporting 60 tonnes of aid. On 22 March 2018, it was announced that the Forestry Corps was merged into the National Fire and Rescue Administration, becoming a purely civilian firefighting agency and losing its law enforcement duties. The 13 Provincial Forestry Corps were converted into Forest Fire Departments; the Mobile Detachment was renamed to the National Fire and Rescue Administration Mobile Detachment.
=== Elimination of gingival enlargement === In cases of gingival enlargement induced by drugs, surgical treatment through a gingivectomy proved to be effective with most patients showing no clinical sign of recurrence after one year. Even though it is the most frequent method of treatment, it is only indicated when overgrowth is severe. Another cause of gingival enlargement would be a hereditary condition known as gingival fibromatosis. The extensive overgrowth of gingival tissue is usually treated with a gingivectomy, as it produces good aesthetic results. However, recurrence in these cases are unpredictable. This means that those affected face the possibility of undergoing repeated procedures.
Sources: en.wikipedia.org
No. Cardarine has not received approval for human therapeutic use in major jurisdictions. It remains an investigational compound.
It is classified as a PPARδ agonist on the WADA Prohibited List. Anti-doping laboratories can detect it and its metabolites in urine. Its use is banned in competition and usually out of competition.
Rodent studies reported increased tumor incidence at multiple sites. The human relevance remains uncertain, but the findings contributed to discontinuation of development. No long-term human cancer data are available.
Cardarine is a common name for GW501516, a synthetic PPARδ agonist developed for research. It has not been approved as a medication in any country. It is classified as an unapproved drug and a prohibited substance in sport.